Complete remission of mantle-cell non-Hodgkin lymphoma with a dendritic cell vaccine  by Massumoto, Celso et al.
case report
Hematol Oncol Stem Cell Ther 2(1)     First Quarter 2009 hemoncstem.edmgr.com302
Non-Hodgkin lymphomas (NHL) include more than 20 different histologic subtypes. The number of cases has doubled in the last 
25 years, particularly in elderly patients. In Brazil, NHL 
represents the fifth most common cancer form with in-
cidence of 55 000 cases a year and the cause of more 
than 26 000 deaths.1
A rare and aggressive form of NHL is mantle-cell 
lymphoma (MCL), which is believed to originate from 
naive B-cells in the mantle zone of lymph nodes and ac-
counts for about 5% to 10% of adult NHL.2 This type 
of cancer is frequently associated with a t(11;14) trans-
location3 resulting in overexpression of the cyclin D1 
gene, routinely used as a diagnostic marker. Common 
chemotherapy approaches include rituximab-CHOP 
(cyclophosphamide, doxorubicin, vincristine, and pred-
nisone) followed by stem cell transplantation or ritux-
imab-HyperCVAD (cyclophosphamide, vincristine, 
doxorubicin, decadron, cytarabine, and methotrexate) 
followed by observation.4,5 Recent studies in patients 
with relapsed MCL have shown substantial antitumor 
activity with single-agent bortezomib, single-agent 
temsirolimus, and the combination of thalidomide and 
rituximab. Unfortunately these approaches are not able 
to cure patients or even promote long-lasting responses 
without severe toxicity.6-8
We present a case with MCL disease that obtained 
complete remission following therapy with dendritic 
cell tumor cell vaccine without the major adverse reac-
tions common in traditional therapies.
CASE 
A 74-year-old white male was diagnosed with MCL 
(cyclin D1+) in 2004 with involvement of the ceccum 
whose ulceration in the mucosa caused gastrointestinal 
bleeding. He was staged as IIIB and received 8 cycles 
of rituximab-CHOP. He remained well until 2006 
when a PET/CT revealed no evidence of disease and 
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he remained in observation without further therapy. 
One year later a PET/CT showed hypercaptation of 
2-fluoro-2-deoxy-D-glucose in the ceccum area and 
other abnormal areas in the rectum. A biopsy revealed 
MCL. The patient was given five cycles of bortezomib 
(at 1.3 mg/m2 on days 1, 4, 8 and 11) every 21 days 
and then stopped due to toxicity. On another PET/CT 
a hyperconcentration area (standardized uptake vari-
able=6.8 was seen in the ceccum and a biopsy revealed 
persistence of disease. A decision was made to operate 
on the patient and the tumor tissue removed from the 
ceccum was used for preparing a vaccine of hybrid den-
dritic-tumor cells. Vaccines were applied intradermally 
in the arm, with applications performed every 4 weeks, 
from November 2007 to May 2008. No side effects 
were seen at the vaccination site. The patient remains 
in complete remission according to a recent PET/CT 
analysis (Figure 1).
DISCUSSION
Mantle cell lymphoma remains one of the most challeng-
ing subtypes of non-Hodgkin lymphoma. Common che-
motherapy approaches are evolving but frequently pro-
mote short responses that can even culminate in drug re-
sistance.4-8 Therapeutic vaccines for MCL are commonly 
based on the tumor-specific immunoglobulin expressed 
on the surface of malignant B-cells. The variable region of 
the immunoglobulin, named idiotype (Id), is the product 
of a unique combination of gene sequences responsible 
for binding to the antigen.9 Phase I, II and III clinical tri-
als using this strategy have shown promising results.10-14 
In one trial, Id-pulsed autologous dendritic cells (DCs) 
were used. There was a clinical response in 22% of the 
patients, demonstrating the feasibility and safety of a DC 
vaccination strategy in humans.15 
In the present work we showed a complete response 
after vaccination with autologous tumor fused to alloge-
neic DC. The patient was in a poor performance status 
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(ECOG 2) and had received 5 cycles of bortezomib, which 
was stopped due to neutropenia and severe neurotoxicity. 
One can argue that the surgery had removed the whole 
tumor, but we speculate that the patient has been in com-
plete remission, according to PET/CT for 7 months. We 
consider this time period to be long for a tumor of 3.5 cm 
in diameter that persisted after 5 cycles of bortezomib.
One of the important advantages of this strategy is 
that the vaccine contains the full tumor cell antigenic 
Figure 1. A PET/CT study was performed 50 minutes after the intravenous injection of 
370 mBq (10 mCi) of F-18 FDG. Pre treatment with surgery and vaccine are represented 
by A and C and post treatment by B and D. Coronal CT, PET and fusion images show 
intense FDG uptake in the right colon area (arrows on A) with maximum uptake value of 
6.8 and none on B. Focal area of FDG uptake in the colon area (transverse CT and fusion 
images) on C and none on D.  
repertoire and does not require the identification of pa-
tient HLA haplotype. This kind of approach was used 
to treat several malignances with promising results.16-19 
Overall the treatment is well tolerated without major 
adverse effects and clinical and immunologic responses 
are observed. The achievement of this complete clinical 
response using a tumor cell-dendritic cell hybrid vac-
cine encourages the use of this procedure in future clini-
cal trials for MCL treatment. 
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